Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference

Journal of Hepatology

Volumn 35, Issue 3, 2001, Pages 421-430

  Bruix, Jordi ^a   Sherman, Morris ^a   Llovet, Josep M ^a   Beaugrand, Michel ^a   Lencioni, Riccardo ^a   Burroughs, Andrew K ^a   Christensen, Erik ^a   Pagliaro, Luigi ^a   Colombo, Massimo ^a   Rodés, Juan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; GEOGRAPHIC DISTRIBUTION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; HUMANS; INCIDENCE; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 0034856294     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00130-1     Document Type: Conference Paper

References (128)

1. Epidemiology of primary liver cancer
2. Rising incidence of hepatocellular carcinoma in the United States
3. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients
4. Independent risk factors for hepatocellular carcinoma in French drinkers
5. Hepatocellular carcinoma in Italian patients with cirrhosis
6. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
7. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost-effectiveness analysis
8. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B
9. Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection and alcohol
10. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in Southern Guangxi, China
11. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study
12. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan
13. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: A prospective study
14. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
15. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
16. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death
17. Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis
18. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis
19. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
20. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan
21. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study
22. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma
23. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein
24. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients
25. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma
26. Macroregenerative nodules in a series of adult cirrhotic liver explants: Issues of classification and nomenclature
27. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis
28. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study
29. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection
30. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis
31. An algorithm for the grading of activity in chronic hepatitis C
32. Epidemiologic approach for cancer screening. Problems in design and analysis of trials
33. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis
34. Screening for hepatocellular carcinoma
35. Growth kinetics of hepatocellular carcinoma
36. Hepatocellular carcinoma in the early stage
37. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients
38. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival
39. Early recognition of hepatocellular carcinoma
40. Alphafetoprotein: An obituary
41. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma - A study based on 420 patients
42. Accuracy of cytology vs. microbiopsy for the diagnosis of well-differentiated hepatocellular carcinoma and macroregenerative nodule. Definition of standardized criteria from a study of 100 cases
43. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy
44. Contrast enhancement of small hepatocellular carcinoma: Usefulness of three successive early image acquisitions during multiphase dynamic MR imaging
45. Optimal phases of dynamic CT for detecting hepatocellular carcinoma: Evaluation of unenhanced and triple-phase images
46. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: Accuracy of helical CT in transplant patients
47. Focal liver lesions: Pattern-based classification scheme for enhancement at arterial phase CT
48. Needle-tract implantation in hepatocellular carcinoma: Frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun
49. Adult cirrhotic liver explants: Precancerous lesions and undetected small hepatocellular carcinomas
50. Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: Correlation with pathologic examination of explanted livers
51. Small hepatocellular carcinoma: Differentiation from adenomatous hyperplasia with color Doppler US and dynamic Gd-DTPA-enhanced MR imaging
52. Hepatocellular carcinoma in the cirrhotic liver: Double-contrast MR imaging for diagnosis
53. Transection of the oesophagus for bleeding oesophageal varices
54. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting
55. Performance status assessment in cancer patients. An inter-observer variability study
56. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients
57. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
58. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
59. Prognosis of hepatocellular carcinoma: The BCLC staging classification
60. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials
61. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival
62. Imaging evaluation of tumor response
63. Reporting results of cancer treatment
64. Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy
65. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan
66. Hepatobiliary surgery
67. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan
68. Hepatocellular carcinoma and the art of prognostication
69. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
70. Limits to liver transplantation in the UK
71. Liver transplantation for hepatocellular carcinoma
72. Right lobe living donor liver transplantation: A review
73. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
74. Liver transplantation for hepatic and biliary malignancy
75. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
76. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
77. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors
78. Percutaneous ethanol injection therapy of hepatocellular carcinoma: Analysis of 77 patients
79. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection
80. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma
81. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection
82. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: Analysis of 71 patients
83. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: Local therapeutic effect and long-term survival rate
84. Ablation of liver tumors using percutaneous RF therapy
85. Microwave coagulation therapy for hepatocellular carcinoma
86. Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: Results, complications, and alcohol ablation
87. Interstitial laser photocoagulation under ultrasound guidance of liver tumors: Results in 104 treated patients
88. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection
89. Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection
90. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
91. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
92. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial
93. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. A prospective randomized study of hepatitis C virus-related liver cancer
94. No treatment, resection and ethanol injection in hepatocellular carcinoma: A retrospective analysis of survival in 391 patients with cirrhosis
95. Percutaneous ethanol injection therapy for hepatocellular carcinoma: Results in 146 patients
96. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: A European experience
97. Long-term survival after ethanol injection for small hepatocellular carcinoma in 100 cirrhotic patients. Relevance of maintained success
98. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
99. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
100. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support
101. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
102. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - A randomized controlled trial
103. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
104. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma
105. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
106. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
107. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial
108. Unresectable hepatocellular carcinoma: A prospective controlled trial with tamoxifen
109. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
110. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients
111. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial
112. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial
113. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial
114. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial
115. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
116. Clinical trials in primary hepatocellular carcinoma: Current status and future directions
117. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy
118. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodol
119. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
120. Oltipraz chemoprevention trial in Qidong, People's Republic of China: Modulation of serum aflatoxin albumin adduct biomarkers
121. International Consensus Conference on Hepatitis C. Consensus statement
122. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
123. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
124. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
125. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
126. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection